No Data
No Data
Prologis Pharmaceutical (000739): Achieving double growth in revenue and profit under a high base
Under the high base for the same period in 2023, the company achieved both revenue and profit growth in the first quarter of 2024. In the first quarter of 2024, the company achieved revenue of 3.198 billion yuan (+3.6%) and net profit of 244 million yuan to mother (+
Guoxin Securities released a research report on April 26 stating that it gave Proplo Pharmaceutical (000739.SZ) a purchase rating. The main reasons for the rating include: 1) Under the high base of the same period in 2023, the company achieved double grow
Guoxin Securities released a research report on April 26 stating that it gave Proplo Pharmaceutical (000739.SZ) a purchase rating. The main reasons for the rating include: 1) Under the high base of the same period in 2023, the company achieved double growth in revenue and profit in the first quarter of 2024; 2) APIs and intermediates sector: revenue increased year-on-year, and gross margin declined; 3) CDMO sector: project growth continued, revenue declined under a high base; 4) formulation sector: R&D investment increased, and the pace of application and approval is expected to accelerate. (Mainichi Keizai Shimbun)
Zhongtai Securities released a research report on April 23 stating that it gave Proplo Pharmaceutical (000739.SZ) a purchase rating. The main reasons for the rating include: 1) in line with expectations, steady growth in performance under industry pressur
Zhongtai Securities released a research report on April 23 stating that it gave Proplo Pharmaceutical (000739.SZ) a purchase rating. The main reasons for the rating include: 1) in line with expectations, steady growth in performance under industry pressure; 2) CDMO: maintaining rapid overall growth and increasing competitive strength; 3) API intermediates: veterinary drug prices are still in the bottom range, the antibiotic series has significant advantages, the market share of core products is rising steadily, focusing on DMF reporting, and steady growth; 4) cost ratio: gross profit ratio and cost ratio have remained stable, and R&D investment has been reduced appropriately. (Mainichi Keizai Shimbun)
Prologis Pharmaceutical (000739): Performance is in line with expectations, growth is resilient
Incident: The company released its 2024 quarterly report. In the first quarter, it achieved operating income of 3.198 billion yuan, a year-on-year increase of 3.65%, and net profit to mother of 244 million yuan, an increase of 1.84% year-on-year, after deducting non-net profit of 239 million yuan
Puluo Pharmaceutical (000739.SZ): At present, we have basically established cooperation with the top 100 chains
On April 19, Ge Longhui Pharmaceutical (000739.SZ) held an investor conference call on April 18, 2024 to discuss “What are the formulation development ideas? What is the status of cooperation with Wazawa Pharmaceutical?” The company replied that the company will consider factors such as product market, product positioning, and clinical value when laying out the types of formulations to be developed. In-hospital formulations are one of the company's most important markets; at the same time, the company is also actively laying out terminal market varieties. With the expansion of the three terminal markets, the expansion of terminal market varieties is inevitable; at present, the company has basically established cooperation with the top 100 chains. Wazawa Pharmaceutical is a company
Prodrug Pharmaceutical (000739.SZ): A key peptide product is expected to enter clinical trials in October this year
On April 19, Ge Longhui Pharmaceutical (000739.SZ) held an investor conference call on April 18, 2024 to discuss “the layout of the company's multiple technology platforms and the future pace of approval for these products?” The company replied that the company's key peptide products are expected to enter clinical trials in October this year and are expected to be approved in mid-2026. In the ADC field, the company is still in the process of screening varieties and setting up projects.
No Data